Oral lysine clonixinate in the acute treatment of migraine: a double-blind placebo-controlled study

• Published in: Arquivos de neuro-psiquiatria Vol. 59; no. 1; pp. 46 - 49
• Main Authors: Krymchantowski, A V, Barbosa, J S, Cheim, C, Alves, L A
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil Academia Brasileira de Neurologia - ABNEURO 01.03.2001
• Subjects: Administration, Oral; Adolescent; Adult; Analgesics - administration & dosage; Clonixin - administration & dosage; Clonixin - analogs & derivatives; Double-Blind Method; Female; Humans; Lysine - administration & dosage; Lysine - analogs & derivatives; Male; Middle Aged; Migraine Disorders - drug therapy; NEUROSCIENCES; Prospective Studies; PSYCHIATRY; migraine; lysine clonixinate; NSAIDs; acute treatment; clonixinato de lisina; tratamento agudo; migrânea
• ISSN: 0004-282X; 1678-4227; 0004-282X
• DOI: 10.1590/S0004-282X2001000100010

Several oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective to treat migraine attacks. Lysine clonixinate (LC) is a NSAID derived from nicotinic acid that has proven to be effective in various pain syndromes such as renal colic and muscular pain. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of oral LC compared to placebo in the acute treatment of migraine. Sixty four patients with the diagnosis of migraine, according to the IHS criteria, were studied prospectively. Patients received LC or placebo once the headache reached moderate or severe intensity for 6 consecutive attacks. With regard to the moderate attacks, LC was superior than placebo after 1, 2 and 4 hours. The consumption of other rescue medications after 4 hours was significantly higher in the placebo group. With regard to the severe attacks, there was no difference between the active drug group and the placebo group concerning headache intensity and consumption of other rescue medications. We conclude that the NSAID lysine clonixinate is effective in treating moderately severe migraine attacks. It is not superior than placebo in treating severe migraine attacks.